NCT02612649View on ClinicalTrials.gov

Special Drug Use Surveillance of Irribow in Female Patients

CompletedOBSERVATIONAL
Enrollment

793

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
DRUG

Ramosetron

Oral

Trial Locations (34)

Unknown

Numakunai

Aichi

Akita

Chiba

Fukui

Fukuoka

Fukushima

Gifu

Gunma

Hiroshima

Hyōgo

Ibaraki

Kagoshima

Kanagawa

Kumamoto

Kyoto

Mie

Miyagi

Miyazaki

Nagano

Niigata

Okayama

Okinawa

Osaka

Ōita

Saitama

Shiga

Shizuoka

Tochigi

Tokyo

Tottori

Toyama

Yamagata

Yamaguchi

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT02612649 - Special Drug Use Surveillance of Irribow in Female Patients | Biotech Hunter | Biotech Hunter